Development and preliminary evaluation of a multivariate index assay for ovarian cancer.

<h4>Background</h4>Most women with a clinical presentation consistent with ovarian cancer have benign conditions. Therefore methods to distinguish women with ovarian cancer from those with benign conditions would be beneficial. We describe the development and preliminary evaluation of a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Suraj D Amonkar, Greg P Bertenshaw, Tzong-Hao Chen, Katharine J Bergstrom, Jinghua Zhao, Partha Seshaiah, Ping Yip, Brian C Mansfield
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2009
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c715c607973f4b38bed54634312ea1ec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c715c607973f4b38bed54634312ea1ec
record_format	dspace
spelling	oai:doaj.org-article:c715c607973f4b38bed54634312ea1ec2021-11-25T06:17:07ZDevelopment and preliminary evaluation of a multivariate index assay for ovarian cancer.1932-620310.1371/journal.pone.0004599https://doaj.org/article/c715c607973f4b38bed54634312ea1ec2009-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19240799/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Most women with a clinical presentation consistent with ovarian cancer have benign conditions. Therefore methods to distinguish women with ovarian cancer from those with benign conditions would be beneficial. We describe the development and preliminary evaluation of a serum-based multivariate assay for ovarian cancer. This hypothesis-driven study examined whether an informative pattern could be detected in stage I disease that persists through later stages.<h4>Methodology/principal findings</h4>Sera, collected under uniform protocols from multiple institutions, representing 176 cases and 187 controls from women presenting for surgery were examined using high-throughput, multiplexed immunoassays. All stages and common subtypes of epithelial ovarian cancer, and the most common benign ovarian conditions were represented. A panel of 104 antigens, 44 autoimmune and 56 infectious disease markers were assayed and informative combinations identified. Using a training set of 91 stage I data sets, representing 61 individual samples, and an equivalent number of controls, an 11-analyte profile, composed of CA-125, CA 19-9, EGF-R, C-reactive protein, myoglobin, apolipoprotein A1, apolipoprotein CIII, MIP-1alpha, IL-6, IL-18 and tenascin C was identified and appears informative for all stages and common subtypes of ovarian cancer. Using a testing set of 245 samples, approximately twice the size of the model building set, the classifier had 91.3% sensitivity and 88.5% specificity. While these preliminary results are promising, further refinement and extensive validation of the classifier in a clinical trial is necessary to determine if the test has clinical value.<h4>Conclusions/significance</h4>We describe a blood-based assay using 11 analytes that can distinguish women with ovarian cancer from those with benign conditions. Preliminary evaluation of the classifier suggests it has the potential to offer approximately 90% sensitivity and 90% specificity. While promising, the performance needs to be assessed in a blinded clinical validation study.Suraj D AmonkarGreg P BertenshawTzong-Hao ChenKatharine J BergstromJinghua ZhaoPartha SeshaiahPing YipBrian C MansfieldPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 2, p e4599 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Suraj D Amonkar Greg P Bertenshaw Tzong-Hao Chen Katharine J Bergstrom Jinghua Zhao Partha Seshaiah Ping Yip Brian C Mansfield Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
description	<h4>Background</h4>Most women with a clinical presentation consistent with ovarian cancer have benign conditions. Therefore methods to distinguish women with ovarian cancer from those with benign conditions would be beneficial. We describe the development and preliminary evaluation of a serum-based multivariate assay for ovarian cancer. This hypothesis-driven study examined whether an informative pattern could be detected in stage I disease that persists through later stages.<h4>Methodology/principal findings</h4>Sera, collected under uniform protocols from multiple institutions, representing 176 cases and 187 controls from women presenting for surgery were examined using high-throughput, multiplexed immunoassays. All stages and common subtypes of epithelial ovarian cancer, and the most common benign ovarian conditions were represented. A panel of 104 antigens, 44 autoimmune and 56 infectious disease markers were assayed and informative combinations identified. Using a training set of 91 stage I data sets, representing 61 individual samples, and an equivalent number of controls, an 11-analyte profile, composed of CA-125, CA 19-9, EGF-R, C-reactive protein, myoglobin, apolipoprotein A1, apolipoprotein CIII, MIP-1alpha, IL-6, IL-18 and tenascin C was identified and appears informative for all stages and common subtypes of ovarian cancer. Using a testing set of 245 samples, approximately twice the size of the model building set, the classifier had 91.3% sensitivity and 88.5% specificity. While these preliminary results are promising, further refinement and extensive validation of the classifier in a clinical trial is necessary to determine if the test has clinical value.<h4>Conclusions/significance</h4>We describe a blood-based assay using 11 analytes that can distinguish women with ovarian cancer from those with benign conditions. Preliminary evaluation of the classifier suggests it has the potential to offer approximately 90% sensitivity and 90% specificity. While promising, the performance needs to be assessed in a blinded clinical validation study.
format	article
author	Suraj D Amonkar Greg P Bertenshaw Tzong-Hao Chen Katharine J Bergstrom Jinghua Zhao Partha Seshaiah Ping Yip Brian C Mansfield
author_facet	Suraj D Amonkar Greg P Bertenshaw Tzong-Hao Chen Katharine J Bergstrom Jinghua Zhao Partha Seshaiah Ping Yip Brian C Mansfield
author_sort	Suraj D Amonkar
title	Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
title_short	Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
title_full	Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
title_fullStr	Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
title_full_unstemmed	Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
title_sort	development and preliminary evaluation of a multivariate index assay for ovarian cancer.
publisher	Public Library of Science (PLoS)
publishDate	2009
url	https://doaj.org/article/c715c607973f4b38bed54634312ea1ec
work_keys_str_mv	AT surajdamonkar developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT gregpbertenshaw developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT tzonghaochen developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT katharinejbergstrom developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT jinghuazhao developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT parthaseshaiah developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT pingyip developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer AT briancmansfield developmentandpreliminaryevaluationofamultivariateindexassayforovariancancer
_version_	1718414009698353152

Development and preliminary evaluation of a multivariate index assay for ovarian cancer.

Ejemplares similares